-
Alimentary Pharmacology & Therapeutics 08/2012; 36(4):398. · 3.77 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Infliximab is effective for induction and maintenance of remission in patients with Crohn's disease. There are few data, however, examining effect of infliximab therapy on management costs of Crohn's disease.
To assess Crohn's disease-related costs of care and resource use in a single-centre cohort of patients with Crohn's disease 12 months pre- and post-infliximab therapy.
Data on 100 consecutive patients receiving infliximab were collected. Crohn's disease-related resource use was collected 12 months pre- and post-infliximab. National Health Service reference costs were applied to these data and the total Crohn's disease-related health service costs per patient were calculated (£UK). The cost of infliximab therapy was not included in our analysis.
Cost savings were demonstrated in all areas of Crohn's disease-related resource use following infliximab therapy. Mean total Crohn's disease-related cost reduction, 12 months following commencement of infliximab therapy, was £2750 per patient. Mean costs at 12 months post-infliximab in responders were lower than in nonresponders (£1656 vs. £3608, P = 0.02). The number of hospitalizations was reduced. Requirements for examination under anaesthesia were also significantly decreased.
Infliximab use resulted in Crohn's disease-related cost savings and hospital resource use, although this was not sufficient to cover the cost of therapy.
Alimentary Pharmacology & Therapeutics 12/2010; 32(11-12):1357-63. · 3.77 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: This article reviews the limitations of existing Crohn's disease therapies and the efficacy and safety of anti-tumour necrosis factor-alpha drugs. Trying to determine which patients may benefit from these therapies while minimizing toxicity is key. Special treatment situations and future developments are also briefly discussed.
British journal of hospital medicine (London, England: 2005) 11/2009; 70(11):644-7. · 0.19 Impact Factor
